Deutsche Bank’s Astria Therapeutics ATXS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,762,802
Closed -$23.1M 3626
2025
Q4
$23.1M Buy
1,762,802
+1,729,463
+5,188% +$20.7M 0.01% 834
2025
Q3
$243K Buy
33,339
+7,113
+27% +$48.1K ﹤0.01% 2956
2025
Q2
$141K Sell
26,226
-9,107
-26% -$44.1K ﹤0.01% 3119
2025
Q1
$189K Sell
35,333
-4,411
-11% -$30.9K ﹤0.01% 2975
2024
Q4
$355K Buy
39,744
+13,986
+54% +$149K ﹤0.01% 2798
2024
Q3
$284K Buy
25,758
+6,634
+35% +$73.8K ﹤0.01% 2746
2024
Q2
$174K Sell
19,124
-5,092
-21% -$49.7K ﹤0.01% 2879
2024
Q1
$341K Buy
24,216
+7,597
+46% +$94.6K ﹤0.01% 2533
2023
Q4
$128K Hold
16,619
﹤0.01% 3111
2023
Q3
$124K Buy
16,619
+3,422
+26% +$29.2K ﹤0.01% 3058
2023
Q2
$110K Buy
+13,197
New +$152K ﹤0.01% 3230
2021
Q2
Sell
-1,967
Closed -$34K 4594
2021
Q1
$34K Sell
1,967
-207
-10% -$3.74K ﹤0.01% 4316
2020
Q4
$28K Buy
2,174
+646
+42% +$11.5K ﹤0.01% 4208
2020
Q3
$57K Buy
1,528
+144
+10% +$5.71K ﹤0.01% 3820
2020
Q2
$53K Buy
+1,384
New +$49.3K ﹤0.01% 3784
2020
Q1
Sell
-889
Closed -$31K 4327
2019
Q4
$31K Buy
+889
New +$28K ﹤0.01% 4141
2019
Q2
Sell
-4,484
Closed -$213K 5278
2019
Q1
$213K Sell
4,484
-10,463
-70% -$355K ﹤0.01% 3961
2018
Q4
$391K Buy
14,947
+10,733
+255% +$406K ﹤0.01% 3487
2018
Q3
$203K Sell
4,214
-3,098
-42% -$139K ﹤0.01% 4231
2018
Q2
$421K Sell
7,312
-1,156
-14% -$107K ﹤0.01% 3931
2018
Q1
$919K Buy
8,468
+4,713
+126% +$471K ﹤0.01% 3363
2017
Q4
$335K Buy
+3,755
New +$442K ﹤0.01% 3797
2017
Q3
Sell
-93
Closed -$7K 4867
2017
Q2
$7K Buy
93
+90
+3,000% +$7.49K ﹤0.01% 4706
2017
Q1
$0 Buy
+3
New +$413 ﹤0.01% 4900
2016
Q3
Sell
-86
Closed -$19K 4901
2016
Q2
$19K Buy
86
+75
+682% +$22.6K ﹤0.01% 4764
2016
Q1
$3K Sell
11
-8
-42% -$2.76K ﹤0.01% 5009
2015
Q4
$8K Sell
19
-7
-27% -$3.36K ﹤0.01% 4964
2015
Q3
$12K Sell
26
-14
-35% -$10K ﹤0.01% 4906
2015
Q2
$29K Buy
+40
New +$30.2K ﹤0.01% 4790

Deutsche Bank's ATXS Position: Q1 2026 in Review

Deutsche Bank sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 1,762,802 shares — an estimated $23.1M sold.

Deutsche Bank first reported a position in ATXS in Q2 2015 and held it in 29 quarters. The position peaked at $23.1M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

  • Deutsche Bank reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Deutsche Bank sold 1,762,802 Astria Therapeutics shares in Q1 2026, an estimated $23.1M.
  • Deutsche Bank first reported a position in Astria Therapeutics in Q2 2015 and held it in 29 quarters.
  • Deutsche Bank's Astria Therapeutics position peaked at $23.1M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.